- Home
- CORT vs NCLH Comparison
CORT vs NCLH Comparison
Compare CORT & NCLH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CORT
- NCLH
- Stock Information
- Founded
- CORT 1998
- NCLH 1966
- Country
- CORT United States
- NCLH United States
- Employees
- CORT N/A
- NCLH N/A
- Industry
- CORT Biotechnology: Pharmaceutical Preparations
- NCLH Marine Transportation
- Sector
- CORT Health Care
- NCLH Consumer Discretionary
- Exchange
- CORT Nasdaq
- NCLH Nasdaq
- Market Cap
- CORT 7.6B
- NCLH 11.5B
- IPO Year
- CORT N/A
- NCLH 2013
- Fundamental
- Price
- CORT $75.18
- NCLH $25.40
- Analyst Decision
- CORT Strong Buy
- NCLH Buy
- Analyst Count
- CORT 4
- NCLH 19
- Target Price
- CORT $139.00
- NCLH $28.33
- AVG Volume (30 Days)
- CORT 675.5K
- NCLH 16.7M
- Earning Date
- CORT 10-29-2025
- NCLH 10-30-2025
- Dividend Yield
- CORT N/A
- NCLH N/A
- EPS Growth
- CORT N/A
- NCLH 61.59
- EPS
- CORT 1.11
- NCLH 1.54
- Revenue
- CORT $716,080,000.00
- NCLH $9,560,994,000.00
- Revenue This Year
- CORT $30.62
- NCLH $8.19
- Revenue Next Year
- CORT $37.68
- NCLH $10.51
- P/E Ratio
- CORT $67.23
- NCLH $16.55
- Revenue Growth
- CORT 25.71
- NCLH 5.22
- 52 Week Low
- CORT $38.68
- NCLH $14.21
- 52 Week High
- CORT $117.33
- NCLH $29.29
- Technical
- Relative Strength Index (RSI)
- CORT 60.68
- NCLH 52.73
- Support Level
- CORT $69.03
- NCLH $25.06
- Resistance Level
- CORT $74.79
- NCLH $27.18
- Average True Range (ATR)
- CORT 2.69
- NCLH 0.91
- MACD
- CORT 0.32
- NCLH -0.03
- Stochastic Oscillator
- CORT 95.68
- NCLH 44.89
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
About NCLH Norwegian Cruise Line Holdings Ltd.
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 71,000). It operates 34 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 13 passenger vessels on order among its brands through 2036, representing 38,400 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.